Rare Daily Staff
Huma Therapeutics raised $200 million in a series C financing to scale its modular platform, which can power digital “hospitals at home” nationally and support the pharmaceutical and research industries to run the larger decentralized clinical trials.
Leaps by Bayer and Hitachi Ventures led the $130 million series C funding round, with participation from Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora, the former president of SoftBank, and Michael Diekmann, the chairman of Allianz. The investors also agreed to a further commitment of $70 million that can be exercised at a later date.
Huma’s platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive care and research. The company’s research at the intersection of predictive care and machine learning has been peer-reviewed and published across a range of scientific and medical journals.
Its digital “hospital at home” was co-created with clinicians and currently helps care for patients across the England National Health Service, Wales, Germany, and the United Arab Emirates. It has been independently shown to almost double clinical capacity, reduce hospital readmissions by more than one third and has patient adherence levels of more than 90 percent.
The service is also supporting governments’ pandemic responses on a not-for-profit basis and is now used for a range of patients including those going through knee- and hip-replacement surgery.
The new investment will be used to expand its digital platform in the United States, Asia, and the Middle East. Huma advanced its work in the United States in 2021 and has already fostered new partnerships with clinical research organizations, healthcare providers, payers, research organizations, and technology companies, which include Stanford Medicine and the Johns Hopkins Bloomberg School of Public Health.
“This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives,” said Dan Vahdat, founder and CEO of Huma. “We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide.”